CerbaXpert
9
2
2
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 9 trials
0%
0 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
Accupower ® HBV Performance Evaluation Quant Kit Bioneer Existation FA 96/384
Role: lead
Accupower ® HCV Performance Evaluation Quant Kit Bioneer Existation™FA 96/384
Role: lead
Longitudinal Evaluation of Antibody Kinetics of Vaccinated Patients With Non-mandatory Vaccine Following Administration of a Non-public Marketed Vaccine in the General Population, Real-life Study
Role: lead
Study of the Transmission of Anti-interferon Type 1 Alpha Autoantibodies From Mother to Child Via the Placental Barrier
Role: lead
Prevalence of Sexually Transmitted Infections (STIs) and Coinfections in the General Population
Role: lead
Collection of Additional Biological Samples From Potentially COVID-19 Patients for Monitoring of Biological Parameters Carried Out as Part of the Routine
Role: lead
Evaluation of the Physiological Stability Variability and Robustness of NIS4
Role: lead
Infectious Prospective Collection for Biological Analysis
Role: lead
Validate Non-invasive Prenatal Tests for the Detection of Chromosomal Abnormalities
Role: lead
All 9 trials loaded